Rachel Cervantes joined Synthetic Genomics in 2018. Previously VP of Corporate Development at the University Science Center in Philadelphia, Rachel brings over 20 years of experience in the commercial and scientific aspects of pharmaceutical innovation within large pharmaceutical, biotech, and academic research environments. She also served as Senior Director of Business Development at Egalet Corporation and held similar roles at Inovio Pharmaceuticals and Merck & Co., where, in addition to evaluating, structuring and negotiating global healthcare partnerships, she also held leadership roles within R&D and Marketing. In addition to her private sector experience, Dr. Cervantes was a research associate at the Salk Institute of Biological Sciences where she conducted NIH-funded cancer research.
She holds an MBA from the Wharton School of Business at the University of Pennsylvania, a Ph.D. in Cellular and Molecular Biology from the University of Cincinnati, and a BA from the University of Hawai’i at Manoa.